Entering text into the input field will update the search result below

Aerie Pharmaceuticals, Inc. (AERI) CEO Vince Anido on Q1 2021 Results - Earnings Call Transcript

May 06, 2021 12:05 AM ETAerie Pharmaceuticals, Inc. (AERI)
SA Transcripts profile picture
SA Transcripts

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Q1 2021 Earnings Conference Call May 5, 2021 5:00 PM ET

Company Participants

Ami Bavishi - Director of IR

Vince Anido - Chairman and CEO

Tom Mitro - President and COO

Rich Rubino - CFO

David Hollander - Chief Research and Development Officer

John LaRocca - General Counsel

Conference Call Participants

Annabel Samimy - Stifel

Serge Belanger - Needham & Company

Stacy Ku - Cowen and Company

Louise Chen - Cantor

Dana Flanders - Guggenheim

Greg Fraser - Truist and Securities

Difei Yang - Mizuho Securities

Frank Brisebois - Oppenheimer

Elliot Wilbur - Raymond James


Good afternoon. Thank you for standing by and welcome to the Aerie Pharmaceuticals First Quarter 2021 Earnings Conference Call. At this time, all participants are in listen-only mode. Later we will conduct a question-and-answer session and instructions will follow at that time. Also today's conference call will be recorded.

It is now my pleasure to turn the floor over to Aerie's Director of Investor Relations, Ami Bavishi. Please go ahead, Ami.

Ami Bavishi

Thank you, Jeff. Good afternoon and thank you for joining us. With us today are Vince Anido, Aerie's Chairman and Chief Executive Officer; Tom Mitro, Aerie's President and Chief Operating Officer; Rich Rubino, Aerie's Chief Financial Officer; David Hollander, Chief Research and Development Officer, and John LaRocca, Aerie's General Counsel. Today's call is also being webcast live on our website investors.aeriepharma.com and it will be available for replay as indicated in our press release.

Now for forward-looking statements and non-GAAP financial measures. On this call, we will make certain forward-looking statements including statements, forecasts, and observations regarding our future financial and operating performance, impacts of the COVID-19 pandemic including our observations regarding ongoing operating expenses and net revenue per bottle. These statements will include observations associated with our commercialization of Rhopressa and Rocklatan

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.